首頁 > 市場調查報告書 > 製藥

癌症生物標記

市場調查報告書

商品編碼

2055270

腫瘤血液檢測市場：按生物標記類型、技術、臨床應用、癌症類型、最終用戶和地區分類

Tumor Blood Testing Market, By Biomarker Type, By Technology, By Clinical Application, By Cancer Type, By End User, By Geography

出版日期: 2026年03月30日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，腫瘤血液檢測市場規模將達到106.9億美元，到2033年將達到275.9億美元。預計從2026年到2033年，該市場將以14.5%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	106.9億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	14.50%	2033年市場規模預測：	275.9億美元

全球腫瘤血液檢測市場是腫瘤診斷領域一個具有變革意義的細分市場，從根本上重塑了現代醫療保健中癌症檢測、監測和治療計劃的方法。

腫瘤血液檢測，也稱為液態切片，包含一系列突破性的非侵入性診斷技術，可分析周邊血液樣本中存在的循環性腫瘤細胞(CTC)、循環腫瘤 DNA (ctDNA)、外泌體和其他腫瘤衍生的生物標記。

這種創新方法相比傳統組織切片檢查具有顯著優勢，包括減輕患者不適、降低手術風險、實現即時監測以及更全面地了解腫瘤異質性。其市場應用範圍廣泛，涵蓋癌症早期篩檢和診斷、治療方法選擇、治療監測以及微量殘存疾病檢測等。

隨著基因測序技術的進步、人工智慧（AI）的融合應用以及越來越多的臨床證據支持液態生物檢體的有效性，腫瘤血液檢測市場正經歷前所未有的成長。全球癌症發生率的上升，以及對精準醫療和個人化治療策略日益成長的需求，持續推動全球不同醫療機構的市場擴張。

市場動態

全球腫瘤血液學市場受多種強烈因素驅動，推動其快速擴張和臨床應用。其中一個關鍵成長要素是全球癌症負擔日益加重。隨著發病率的上升，人們對更有效率、更便捷、更人性化的診斷解決方案的需求日益成長，這些方案能夠實現早期檢測，並在整個治療過程中進行持續監測。

次世代定序、數位PCR和分子譜分析技術的進步顯著提高了液態生物檢體的敏感度和特異性，使其成為侵入性組織取樣手術日益可行的替代方案。精準醫療和個人化治療方案的日益普及進一步加速了市場成長，因為腫瘤血液檢測能夠以前所未有的精確度即時監測治療反應、抗藥性機制和疾病進展。然而，該市場也面臨著許多限制因素，包括先進檢測平台的高成本、許多地區有限的醫保覆蓋以及新型診斷技術監管方面的複雜性。

此外，醫療保健系統缺乏標準化的流程、品管措施和臨床指南，這給實施帶來挑戰，並阻礙了技術的廣泛應用。儘管有這些限制，但透過在早期癌症篩檢計畫中擴大應用、整合人工智慧（AI）和機器學習平台以提高診斷準確性以及加大研發投入，仍湧現出巨大的機會。加強製藥公司、診斷設備製造商和醫療機構之間的合作，預示著市場擴張的巨大潛力。這種潛力在新興國家尤為顯著，這些國家傳統的切片檢查基礎設施仍然有限，而對癌症診斷的需求卻持續快速成長。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數分析了全球腫瘤血液檢測市場的主要參與者：公司亮點、產品系列、關鍵亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球腫瘤血液檢測市場報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等行業相關人員相關者。
透過分析全球腫瘤血液檢測市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第10章競爭格局

Hoffmann-La Roche Ltd.
Illumina, Inc.
Guardant Health
Bio-Rad Laboratories
Abbott Laboratories
Qiagen
Agilent Technologies
Thermo Fisher Scientific
Siemens Healthineers
GE Healthcare
BD（Becton, Dickinson and Company）
PerkinElmer
Myriad Genetics
Sysmex Corporation
Danaher Corporation

第11章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第12章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI8830

Tumor Blood Testing Market is estimated to be valued at USD 10.69 Bn in 2026 and is expected to reach USD 27.59 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 10.69 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	14.50%	2033 Value Projection:	USD 27.59 Bn

The global tumor blood testing market represents a transformative segment within the broader oncology diagnostics landscape, fundamentally reshaping how cancer detection, monitoring, and treatment decisions are approached in modern healthcare.

Tumor blood testing, also known as liquid biopsy, encompasses a revolutionary array of non-invasive diagnostic techniques that analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other tumor-derived biomarkers present in peripheral blood samples.

This innovative approach offers significant advantages over traditional tissue-based biopsies, including reduced patient discomfort, lower procedural risks, real-time monitoring capabilities, and the ability to capture tumor heterogeneity more comprehensively. The market encompasses various applications ranging from early cancer screening and diagnosis to treatment selection, therapeutic monitoring, and minimal residual disease detection.

With advancing genomic sequencing technologies, artificial intelligence integration, and growing clinical evidence supporting liquid biopsy efficacy, the tumor blood testing market is experiencing unprecedented growth momentum. The increasing prevalence of cancer globally, coupled with rising demand for precision medicine approaches and personalized treatment strategies, continues to drive market expansion across diverse healthcare settings worldwide.

Market Dynamics

The global tumor blood testing market is propelled by several compelling drivers that underscore its rapid expansion and clinical adoption. The primary growth driver stems from the increasing global cancer burden, with rising incidence rates necessitating more efficient, accessible, and patient-friendly diagnostic solutions that can facilitate early detection and continuous monitoring throughout treatment journeys.

Technological advancements in next-generation sequencing, digital PCR, and molecular profiling techniques have significantly enhanced the sensitivity and specificity of liquid biopsies, making them increasingly viable alternatives to invasive tissue sampling procedures. The growing emphasis on precision medicine and personalized treatment approaches further accelerates market growth, as tumor blood testing enables real-time monitoring of treatment response, resistance mechanisms, and disease progression with unprecedented accuracy. However, the market faces notable restraints including high costs associated with advanced testing platforms, limited reimbursement coverage in many regions, and regulatory complexities surrounding novel diagnostic technologies.

Additionally, the lack of standardized protocols, quality control measures, and clinical guidelines across different healthcare systems creates implementation challenges that may hinder widespread adoption. Despite these constraints, substantial opportunities emerge through expanding applications in early-stage cancer screening programs, integration with artificial intelligence and machine learning platforms for enhanced diagnostic accuracy, and growing investments in research and development activities. The increasing collaboration between pharmaceutical companies, diagnostic manufacturers, and healthcare institutions presents significant potential for market expansion, particularly in emerging economies where traditional biopsy infrastructure remains limited but demand for cancer diagnostics continues to grow exponentially.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global tumor blood testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Illumina, Inc., Guardant Health, Bio-Rad Laboratories, Abbott Laboratories, Qiagen, Agilent Technologies, Thermo Fisher Scientific, Siemens Healthineers, GE Healthcare, BD (Becton, Dickinson and Company), PerkinElmer, Myriad Genetics, Sysmex Corporation, and Danaher Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global tumor blood testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor blood testing market

Market Segmentation

Biomarker Type Insights (Revenue, USD Bn, 2021 - 2033)
Circulating Tumor DNA (ctDNA)
Circulating Tumor Cells (CTCs)
Extracellular Vesicles (EVs) / Exosomes
Other Cell-Free Nucleic Acids
Technology Insights (Revenue, USD Bn, 2021 - 2033)
Polymerase Chain Reaction (PCR)-Based Testing
Next-Generation Sequencing (NGS)
Microarray-Based Testing
Mass Spectrometry
Immunoassays
Clinical Application Insights (Revenue, USD Bn, 2021 - 2033)
Early Detection/Cancer Screening
Diagnosis
Therapy Selection
Treatment Monitoring
Minimal Residual Disease (MRD) Detection
Recurrence Monitoring/Prognosis
Cancer Type Insights (Revenue, USD Bn, 2021 - 2033)
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Bladder Cancer
Melanoma
Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
End User Insights (Revenue, USD Bn, 2021 - 2033)
Hospitals
Specialty Clinics
Diagnostic Laboratories
Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Hoffmann-La Roche Ltd.
Illumina, Inc.
Guardant Health
Bio-Rad Laboratories
Abbott Laboratories
Qiagen
Agilent Technologies
Thermo Fisher Scientific
Siemens Healthineers
GE Healthcare
BD (Becton, Dickinson and Company)
PerkinElmer
Myriad Genetics
Sysmex Corporation
Danaher Corporation

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Tumor Blood Testing Market, By Biomarker Type
- Global Tumor Blood Testing Market, By Technology
- Global Tumor Blood Testing Market, By Clinical Application
- Global Tumor Blood Testing Market, By Cancer Type
- Global Tumor Blood Testing Market, By End User
- Global Tumor Blood Testing Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Tumor Blood Testing Market, By Biomarker Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Circulating Tumor DNA (ctDNA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Circulating Tumor Cells (CTCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Extracellular Vesicles (EVs) / Exosomes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Other Cell-Free Nucleic Acids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Tumor Blood Testing Market, By Technology, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Polymerase Chain Reaction (PCR)-Based Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Next-Generation Sequencing (NGS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Microarray-Based Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Mass Spectrometry
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Immunoassays
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Tumor Blood Testing Market, By Clinical Application, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Early Detection/Cancer Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Therapy Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Treatment Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Minimal Residual Disease (MRD) Detection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Recurrence Monitoring/Prognosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Tumor Blood Testing Market, By Cancer Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Tumor Blood Testing Market, By End User, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Tumor Blood Testing Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Guardant Health
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bio-Rad Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Qiagen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Agilent Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Siemens Healthineers
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GE Healthcare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BD (Becton, Dickinson and Company)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
PerkinElmer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Myriad Genetics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sysmex Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies